Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 8/20 | 0.57 |
| ▸ | PROKR1 | Q8TCW9 | 8/20 | 0.57 |
| ▸ | MMP12 | P39900 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4673429 | 0.81 | FPR2 (0.50) | FPR2PROKR1MMP12MMP13SMN1; SMN2 | |
| SCHEMBL7076681 | 0.78 | ACLY (0.60) | FPR2PROKR1MMP13SMN1; SMN2MAPT | |
| SCHEMBL27028609 | 0.78 | SLC6A4 (0.62) | FPR2PROKR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL22642435 | 0.77 | SLC6A4 (0.50) | FPR2PROKR1MMP12MMP13SLC6A4 | |
| SCHEMBL8302495 | 0.77 | HRH3 (0.63) | FPR2PROKR1SMN1; SMN2SLC6A4SLC6A2 | |
| SCHEMBL12099594 | 0.77 | EPHX2 (0.48) | FPR2PROKR1MMP12MMP13SMN1; SMN2 | |
| SCHEMBL4702501 | 0.76 | FPR2 (0.51) | FPR2PROKR1MMP12MMP13SMN1; SMN2 | |
| SCHEMBL4698150 | 0.76 | FPR2 (0.51) | FPR2PROKR1MMP12MMP13SMN1; SMN2 | |
| SCHEMBL4698148 | 0.76 | FPR2 (0.51) | FPR2PROKR1MMP12MMP13SMN1; SMN2 | |
| SCHEMBL1256120 | 0.75 | EPHX2 (0.60) | EPHX2HRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215010-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | VASA THERAPEUTICS SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2025-07-03 | — | — | US | disclosed |
| CN-119923399-A | Useful as matrix metalloproteinase inhibitors diazabicyclooctane derivatives of (a) | 瓦萨治疗有限责任公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4499647-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | Vasa Therapeutics Spolka Z Orgraniczona Odpowiedzialnoscia (PL) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023187670-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | VASA THERAPEUTICS SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023187670-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | VASA THERAPEUTICS SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2023-10-05 | — | — | WO | disclosed |
| WO-2008147764-A1 | MMP INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215010-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | MMP1, MMP9, MMP8 | FPR2 2496/4885PROKR1 3438/4885MMP12 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.